Onconetix, Inc. (ONCO)

NASDAQ: ONCO · Real-Time Price · USD

4.730

-1.570 (-24.92%)

At close: Jun 13, 2025, 4:00 PM

4.780

+0.050 (1.06%)

After-hours: Jun 13, 2025, 7:58 PM EDT

Onconetix Employees

Onconetix had 5 employees as of December 31, 2024. The number of employees decreased by 7 or -58.33% compared to the previous year.

Employees

5

Change (1Y)

-7

Growth (1Y)

-58.33%

Revenue / Employee

$385,063

Profits / Employee

-$11,498,966

Market Cap

2.47M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	5	-7	-58.33%
Dec 31, 2023	12	0	-
Dec 31, 2022	12	7	140.00%
Dec 31, 2021	5	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

ONCO News

2 days ago - Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders - GlobeNewsWire
22 days ago - Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - GlobeNewsWire
22 days ago - Onco-Innovations Uplists to Cboe Canada - Business Wire
2 months ago - Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort - GlobeNewsWire
3 months ago - Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress - GlobeNewsWire
6 months ago - Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing - GlobeNewsWire
8 months ago - Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board - Business Wire
9 months ago - Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit - GlobeNewsWire